Drug–Drug Interaction Between Dihydroartemisinin–Piperaquine and Sulfadoxine‐Pyrimethamine During Malaria Chemoprevention in Pregnant Women
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3471 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Norah Mwebaza und 19 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Research Collaboration, Kampala, Uganda. Hauptthemen laut MEDLINE: Antimalarials, Artemisinins, Malaria, Pregnancy Complications, Parasitic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Co‐administration of dihydroartemisinin–piperaquine (DP) and sulfadoxine‐pyrimethamine (SP) for intermittent preventive treatment of malaria in pregnancy (IPTp) may be superior in preventing adverse birth outcomes compared with either therapy alone, but potential drug–drug interactions require investigation. We conducted intensive and sparse pharmacokinetic (PK) studies in a subset of Ugandan women participating in a randomized controlled trial of monthly IPTp with SP vs. DP vs. DP + SP. Intensive PK sampling was performed from day 0 to 23 after dosing at 28 weeks gestation in 87 participants across treatment arms. Sparse sampling was performed on day 28 (trough) after dosing at 20 and 28 gestational weeks in additional 196 participants receiving SP vs. DP + SP. Intensive PK analysis demonstrated that compared with SP alone, co‐administration of DP + SP was associated with lower maximal concentrations, the area under the concentration–time curves (AUC), and day 23 concentrations of sulfadoxine (25%, 25%, and 27%) and pyrimethamine (26%, 34%, and 32%) ( P < 0.05 for all comparisons). Sparse PK results demonstrated participants co‐administered DP + SP had lower trough concentrations after dosing at 20 and 28 gestational weeks for sulfadoxine (6%, P = 0.68 and 31%, P = 0.023, respectively) and pyrimethamine (18%, P = 0.032 and 33%, P < 0.001, respectively) compared with SP alone. Co‐administration of DP + SP was associated with a 19% reduction in piperaquine AUC ( P = 0.046), but no significant difference in other PK parameters compared with DP alone. In summary, co‐administration of DP + SP was associated with significantly reduced SP exposure, with a greater magnitude during the third vs. second trimester. The clinical consequences of this interaction are yet unknown.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Disease Research Collaboration, Kampala, Uganda.
- Department of Pharmacology and Therapeutics, Makerere University, Kampala, Uganda.
- Institute for Global Health Sciences, University of California San Francisco, San Francisco, California, USA.
- Department of Clinical Pharmacy, University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA.
- Department of Life Sciences, University of Bath, Bath, UK.
- Department of Medicine, Makerere University, Kampala, Uganda.
ORCID-Profile: Michelle E Roh, Nikoletta Fotaki, Abel Kakuru, Jimmy Kizza, Moses Kamya, Philip J Rosenthal, Francesca T Aweeka, Liusheng Huang
Förderung
- NICHD NIH HHS
- NIAID NIH HHS
Zitieren
APA
Mwebaza, N., Roh, M. E., Geng, Y. Z., Opio, L., Opira, B., Marzan, F., Mwima, M. W., Ssemukuye, T., Guo, K., Gingrich, D., Fotaki, N., Kakuru, A., Kizza, J., Aguti, M., Adrama, H., Kamya, M., Dorsey, G., Rosenthal, P. J., Aweeka, F. T., & Huang, L. (2025). Drug–Drug Interaction Between Dihydroartemisinin–Piperaquine and Sulfadoxine‐Pyrimethamine During Malaria Chemoprevention in Pregnant Women. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3471
Vancouver
Mwebaza N, Roh ME, Geng YZ, Opio L, Opira B, Marzan F, et al. Drug–Drug Interaction Between Dihydroartemisinin–Piperaquine and Sulfadoxine‐Pyrimethamine During Malaria Chemoprevention in Pregnant Women. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3471
BibTeX
@article{Mwebaza2025,
author = {Mwebaza, Norah and Roh, Michelle E and Geng, Yourong Z and Opio, Leonard and Opira, Bishop and Marzan, Florence and Mwima, Moses W and Ssemukuye, Timothy and Guo, Kevin and Gingrich, David and Fotaki, Nikoletta and Kakuru, Abel and Kizza, Jimmy and Aguti, Miriam and Adrama, Harriet and Kamya, Moses and Dorsey, Grant and Rosenthal, Philip J and Aweeka, Francesca T and Huang, Liusheng},
title = {Drug–Drug Interaction Between Dihydroartemisinin–Piperaquine and Sulfadoxine‐Pyrimethamine During Malaria Chemoprevention in Pregnant Women},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3471}
}
EUVIMED